BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12476042)

  • 1. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin.
    Oztürk MA; Barişta I; Altundağ MK; Türker A; Yalçin S; Celik I; Güllü I; Güler N; Ozişik Y; Kars A; Kansu E; Baltali E; Tekuzman G
    Chemotherapy; 2002 Dec; 48(5):252-8. PubMed ID: 12476042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Harting R; Venugopal P; Gregory SA; O'brien T; Bogdanova E
    Clin Lymphoma Myeloma; 2007 May; 7(6):406-12. PubMed ID: 17621406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
    Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
    Choi CW; Paek CW; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
    J Korean Med Sci; 2002 Oct; 17(5):621-4. PubMed ID: 12378012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
    Wang WS; Chiou TJ; Liu JH; Fan FS; Yen CC; Tung SL; Chen PM
    Jpn J Clin Oncol; 1999 Jan; 29(1):33-7. PubMed ID: 10073149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas.
    Nückel H; Dürig J; Dührsen U
    Ann Hematol; 2003 Aug; 82(8):481-486. PubMed ID: 12910375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
    Rodriguez MA; Cabanillas FC; Velasquez W; Hagemeister FB; McLaughlin P; Swan F; Romaguera JE
    J Clin Oncol; 1995 Jul; 13(7):1734-41. PubMed ID: 7602363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients.
    Soussain C; Souleau B; Gabarre J; Zouabi H; Sutton L; Boccaccio C; Albin N; Charlotte F; Merle-Béral H; Delort J; Binet JL; Leblond V
    Leuk Lymphoma; 1999 May; 33(5-6):543-50. PubMed ID: 10342581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Prayoonwiwat W; Numbenjapon T; Assawametha N; O'Charoen R; Swasdikul D
    Clin Lymphoma; 2000 Dec; 1(3):219-25. PubMed ID: 11707834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
    Labrador J; Cabrero-Calvo M; Pérez-López E; Mateos MV; Vázquez L; Caballero MD; García-Sanz R
    Ann Hematol; 2014 Oct; 93(10):1745-53. PubMed ID: 24863692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.
    Sym SJ; Lee DH; Kang HJ; Nam SH; Kim HY; Kim SJ; Eom HS; Kim WS; Suh C
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):27-33. PubMed ID: 18839172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
    Martínez C; Díaz-López A; Rodriguez-Calvillo M; García-Sanz R; Terol MJ; Pérez-Ceballos E; Jiménez MJ; Cantalapiedra A; Domingo-Domenech E; Rodriguez MJ; Sampol A; Espeso M; López FJ; Briones J; García JF; Sureda A;
    Br J Haematol; 2016 Sep; 174(6):859-67. PubMed ID: 27185197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
    Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
    J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
    Velasquez WS; McLaughlin P; Tucker S; Hagemeister FB; Swan F; Rodriguez MA; Romaguera J; Rubenstein E; Cabanillas F
    J Clin Oncol; 1994 Jun; 12(6):1169-76. PubMed ID: 8201379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas.
    Caballero MD; Amigo ML; Hernández JM; Vazquez L; del Cañizo C; Gonzalez M; García R; San Miguel JF
    Ann Hematol; 1997 Feb; 74(2):79-82. PubMed ID: 9063377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.
    Park SH; Kim S; Ko OB; Koo JE; Lee D; Jeong YP; Huh J; Kim SB; Kim SW; Lee JL; Suh C
    Korean J Intern Med; 2006 Sep; 21(3):159-64. PubMed ID: 17017664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
    Bo LJ; Liang AB; Liu B; Chen YH; Wang F; Jin XP
    Ai Zheng; 2006 Dec; 25(12):1553-6. PubMed ID: 17166385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.